Rivanna Medical

Rivanna Medical is a private, commercial-stage medical device company leveraging a unified AI and 3D ultrasound platform to tackle two high-need clinical areas: spinal needle guidance and bedside fracture triage. The company has secured FDA clearance for its initial Accuro 3S device, validated its technology through government grants and clinical studies, and is pursuing 510(k) pathways for its next-generation products. With a combined total addressable market (TAM) exceeding $3.4 billion, Rivanna is positioned at the intersection of point-of-care ultrasound and AI-driven diagnostics, seeking strategic investment to scale its platform.

Unified AI and 3D ultrasound platform featuring deep learning for anatomical analysis, a robotic 3D volumetric transducer for automated acquisition, Dual-Array technology for enhanced needle visibility, and SafeTrack sensor-based needle tracking.

Rivanna competes in the point-of-care ultrasound and AI medical imaging spaces. Direct competitors include large players like GE Healthcare, Philips, and Butterfly Network, which are adding AI capabilities to their portable devices. For fracture detection, it may face specialized AI radiology software companies. Its differentiation lies in its dedicated, integrated hardware/software platform for specific, high-variability clinical workflows.